CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

NA (no intervention)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug104 BVRS-GamVac-Combi Wiki 1.00
drug1003 placebo Wiki 0.38

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D013577 Syndrome NIH 0.15
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 How Immune Responses Shape Virological and Clinical Characteristics of COVID-19: a Prospective Cohort Study

This single-center prospective observational study will examine immune responses to to SARS-CoV-2 and how they correlate with its virological characteristics and clinical manifestations in infected patients. Household contacts will also be included so that early immune responses and viral kinetics can be captured. Patients and contacts will be followed for 8 and 2 weeks, respectively. The study will include a maximum of 250 participants.

NCT04329546 SARS-CoV-2 Viral Kinetics and Host Immune Responses Other: NA (no intervention)

Primary Outcomes

Description: Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2 assessed by ELISA at 28 days after diagnosis/suspected diagnosis

Measure: Immunogenicity primary outcome: Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2 assessed by ELISA at 28 days

Time: assessed at 28 days after diagnosis/presumed diagnosis

Description: Peak viral load in the 56 days following diagnosis/suspected diagnosis, quantified by real-time reverse-transcriptase polymerase chain reaction (RT-PCR) on nasopharyngeal swabs.

Measure: Virologic primary outcome: Peak viral load in the 56 days following diagnosis/suspected diagnosis

Time: 56 days after diagnosis/presumed diagnosis

No related HPO nodes (Using clinical trials)